What This Bill Does
This bill would direct federal support toward research on polycystic kidney disease, a genetic disorder that causes cysts to grow in the kidneys and can lead to kidney failure. It is aimed at improving scientific understanding, speeding up treatment development, and strengthening the research pipeline around diagnosis, care, and long-term outcomes. The measure is in the House and has been referred to the Energy and Commerce Committee for consideration. It is sponsored by Rep. Debbie Wasserman Schultz of Florida and has three cosponsors.
- Supports federal research on polycystic kidney disease (PKD).
- Referred to the House Committee on Energy and Commerce.
- Introduced in the House on June 4, 2026.
- Sponsored by Rep. Debbie Wasserman Schultz (D-FL).
- Has three cosponsors.
Who This Bill Affects
For people living with polycystic kidney disease, this bill could increase the chances of better diagnostics, more research funding, and eventually improved treatments. For the general public, the effect is indirect: it would mainly influence federal health research priorities rather than changing day-to-day benefits or costs immediately.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- PKD patients and family caregivers They want faster progress on treatments that can slow kidney damage and delay dialysis or transplant. Research funding can also improve diagnosis and help families better understand inherited risk.
- Kidney disease researchers and medical centers Dedicated federal support can expand clinical studies, data collection, and translational research. That helps move promising lab findings toward therapies that doctors can actually use.
- Patient advocacy organizations Targeted research bills can raise the profile of underrecognized diseases and help direct attention to conditions with high long-term costs and limited treatment options. They often argue that modest federal investment now can reduce future medical burdens.
- Fiscal conservatives They may argue that Congress should avoid creating or expanding disease-specific research priorities without offsetting cuts elsewhere. Their concern is that narrowly targeted funding can fragment federal health spending.
- Budget watchdogs They may question whether a new research emphasis duplicates existing NIH or kidney-disease programs. They often prefer broader, competitive research funding rather than disease-specific directives.
- Advocates for other medical conditions Some groups may worry that singling out one disease can draw attention and resources away from other serious illnesses. Their argument is usually about fairness and how limited research dollars are allocated.
Key Implications
-
““To support polycystic kidney disease research””
This signals a federal push to improve scientific study of PKD. In practice, that can mean more grants, more clinical research, and a better evidence base for doctors and patients.
-
““Referred to the House Committee on Energy and Commerce””
The bill is now in the committee that handles health policy and biomedical issues. Committee review is where lawmakers decide whether to hold hearings, revise the measure, or move it forward.
-
““Introduced in House””
The measure has entered the legislative process but has not yet advanced to floor debate or votes. At this stage, its immediate effect is procedural rather than operational.
-
““and for other purposes””
This phrase usually allows the bill to include related administrative or technical provisions beyond the main research goal. Those additions can affect how the program is implemented or how agencies carry out the policy.
Latest Status
June 4, 2026
Referred to the House Committee on Energy and Commerce.
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.